Financial Performance - In 2024, the company achieved a revenue of 852 million CNY, a year-on-year decline of 18.53% [2] - The net profit attributable to shareholders increased by 137.09% to 92.46 million CNY [2] - Operating costs decreased by 26.58%, sales expenses by 13.58%, and management expenses by 2.50% [1] Business Segments - The bioproducts segment experienced a year-on-year decline of 20.5% [2] - The company plans to focus on blood products, enhancing production capacity and resource integration [2] - The company currently operates 21 plasma collection stations across various regions [3] Future Growth Strategies - The company aims to increase blood product output with the launch of the Yunnan blood product project [4] - The revival of the Langfang rabies vaccine production is expected to contribute to new revenue streams [4] - The introduction of new diagnostic products is anticipated to offset revenue impacts from centralized procurement policies [4] Industry Outlook - The blood products market in China is projected to reach 60 billion CNY in 2024, with a compound annual growth rate (CAGR) of 11.6% expected until 2027 [8] - The in vitro diagnostics market is expected to grow at a CAGR of 5-8% over the next five years [8]

Core Viewpoint - The blood products industry is experiencing a significant divergence in performance among companies, with some reporting growth while others face declines in revenue and profit [1][2]. Group 1: Company Performance in 2024 - Shanghai Laisai (002252) and Tiantan Biological (600161) reported revenue growth of 2.67% and 16.44% respectively, with net profits increasing by 23.25% and 39.58% [1]. - Hualan Biological (002007), Boya Biological (300294), and Bohui Innovation (300318) experienced revenue declines of 18.02%, 34.58%, and 18.53% respectively, while Hualan's net profit fell by 26.57% [1]. - Bohui Innovation managed to turn a profit with a net profit of 0.09 billion yuan, compared to a loss in the previous year [1]. Group 2: Q1 2025 Performance - In Q1 2025, Tiantan Biological, Hualan Biological, and Boya Biological continued to show revenue growth, while Shanghai Laisai, Tiantan Biological, and Paillin Biological saw revenue declines of 2.45%, 0.57%, and 14% respectively [1]. - Hualan Biological's net profit increased by 19.62%, while Shanghai Laisai and Tiantan Biological reported net profit declines of 25.2% and 22.9% respectively [1]. - The decline in profits for Tiantan Biological was attributed to a decrease in product prices that outweighed the benefits of increased sales volume [1]. Group 3: Market Dynamics - The blood products market is expected to maintain stable growth in 2024, with significant competition in the human albumin market due to increased imports [2][3]. - The cancellation of certain medical insurance restrictions is expected to release market demand for coagulation factor products, contributing to their growth [2]. - The overall price trend for blood products is declining, influenced by increased competition and supply exceeding demand for certain products [3]. Group 4: Industry Consolidation - The blood products industry is characterized by high entry barriers, with fewer than 30 companies currently operating due to strict regulations on blood product production [6][7]. - Recent mergers and acquisitions are expected to enhance industry concentration, with leading companies gaining competitive advantages through resource acquisition [6][7]. - Companies like Tiantan Biological and Shanghai Laisai have made significant acquisitions to expand their production capabilities and market presence [7]. Group 5: Market Size and Growth Projections - The blood products market in China reached a scale of 600 billion yuan in 2024, with projections to grow to 780 billion yuan by 2027, reflecting a compound annual growth rate of 11.6% from 2022 to 2027 [8].

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-022 北京博晖创新生物技术集团股份有限公司 第八届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第十次会议于 2025 年 4 月 28 日在公司会议室召开，会议通知于 2025 年 4月 17日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司监事 会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议应出 席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和《公 司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2025 年第一季度报告》 监事会认为：公司结合 2025 年第一季度的实际经营管理情况编制的《2025 年 第一季度报告》符合《深圳证券交易所创业板股票上市规则》、《上市公司信息披露 管理办法》等法律法规的相关要求。其内容真实、准确、完整的反映了公司 202 ...

Financial Performance - The company reported a basic earnings per share of -0.0050 yuan for Q1 2025, a decrease of 120.58% compared to 0.0243 yuan in Q1 2024 [1] - Net profit for Q1 2025 was -0.04 billion yuan, down 120% from 0.2 billion yuan in Q1 2024 [1] - Operating revenue decreased by 22.9% to 2.02 billion yuan in Q1 2025 from 2.62 billion yuan in Q1 2024 [1] - The return on equity was -0.29% in Q1 2025, a significant decline from 1.44% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders hold a total of 49,925.97 million shares, accounting for 62.52% of the circulating shares, with a change of 1,163.3 million shares from the previous period [1] - The largest shareholder, Du Jiangtao, holds 31,881.14 million shares, representing 39.92% of the total share capital, with no change [2] - Hong Hao, the second-largest shareholder, holds 10,281.00 million shares, also with no change [2] - Yang Qi reduced his holdings by 41.72 million shares, now holding 1,801.34 million shares [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

Financial Performance - The company's revenue for Q1 2025 was ¥201,657,154.39, a decrease of 23.05% compared to ¥262,051,377.78 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥4,054,437.18, representing a decline of 120.41% from a profit of ¥19,863,584.33 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0050, down 120.58% from ¥0.0243 in the same quarter last year[5] - Total operating revenue decreased to ¥201,657,154.39 from ¥262,051,377.78, representing a decline of approximately 23% year-over-year[30] - Net profit for the period was -¥57,221.71, compared to a net profit of ¥42,022,580.71 in the previous period, indicating a significant decline[31] - The company reported a loss attributable to the parent company of -¥4,054,437.18, down from a profit of ¥19,863,584.33 in the prior year[31] Cash Flow - The net cash flow from operating activities was negative at ¥29,492,711.31, a decrease of 192.42% compared to ¥31,910,106.63 in Q1 2024[5] - The cash flow from operating activities showed a significant decline, primarily due to decreased sales revenue and collections[15] - Cash inflow from operating activities totaled $209,449,597.29, down 24.5% from $277,422,518.85 in the previous period[35] - Net cash outflow from operating activities was -$29,492,711.31, compared to a positive cash flow of $31,910,106.63 in the previous period[35] - The company reported a cash inflow of $13,302,406.95 from other operating activities, up 99.5% from $6,695,622.97 in the previous period[35] - The net cash flow from investing activities was -$36,581,934.80, compared to -$72,546,642.65 in the previous period, indicating improved investment efficiency[36] Assets and Liabilities - Total assets increased by 6.21% to ¥4,381,583,602.25 from ¥4,125,558,100.42 at the end of the previous year[5] - Total liabilities rose to ¥2,032,224,210.96 from ¥1,776,429,561.09, an increase of about 14.4%[26] - The total equity attributable to shareholders decreased slightly to ¥1,374,920,641.38 from ¥1,378,686,990.40, a decline of about 0.3%[27] - Long-term borrowings rose by 71.03% to ¥666,819,504.06, primarily due to increased loans from subsidiaries[10] - The company’s long-term borrowings increased to ¥666,819,504.06 from ¥389,879,354.06, indicating a rise of approximately 71%[26] Financing Activities - The company reported a significant increase in cash received from financing activities, totaling ¥286,000,000.00, up 209.19% from ¥92,500,000.00 in the previous year[15] - Cash inflow from financing activities increased significantly to $800,982,649.36, up 184.5% from $281,668,207.13 in the previous period[36] - Net cash flow from financing activities was $269,889,430.99, compared to $26,943,879.85 in the previous period, indicating a strong financing position[36] - The company received $514,982,649.36 in borrowings, significantly higher than $189,168,207.13 in the previous period, reflecting increased leverage[36] Operational Highlights - The company received government subsidies amounting to ¥820,053.86, which are closely related to its normal business operations[7] - The company’s subsidiary, Guangdong Weilin Biological Pharmaceutical Co., Ltd., received a single plasma collection license from the Inner Mongolia Health Commission, allowing it to operate two plasma collection stations[19] - The company’s subsidiary, Bohui Biological Pharmaceutical Co., Ltd., received approval for clinical trials of a trivalent influenza virus subunit vaccine from the National Medical Products Administration[19] - The company signed a guarantee contract with Bank of Communications, agreeing to provide a maximum guarantee of ¥10,300,000 for its subsidiary[20] - The company applied for a loan of ¥500,000,000 from Industrial and Commercial Bank of China, with a term of 7 years, backed by various collateral including equity and property[21] Inventory and Receivables - Accounts receivable increased to ¥71,865,977.47 from ¥58,575,220.53, indicating a rise of about 22.6%[24] - Inventory levels stood at ¥1,026,038,590.79, slightly up from ¥1,011,258,014.00, reflecting a growth of approximately 1.5%[24] - The company’s total current assets amounted to ¥1,471,574,373.76, compared to ¥1,226,324,965.41 at the start of the period, marking an increase of around 20%[24] Financial Expenses - The company experienced a 31.94% increase in financial expenses, amounting to ¥8,271,572.14, attributed to higher interest expenses and bank guarantee fees[12] - Research and development expenses were ¥13,846,347.86, slightly down from ¥14,556,648.09, reflecting a decrease of about 5%[30]

北京博晖创新生物技术集团股份有限公司 内部控制审计报告 大华内字[2025]0011000019 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 北京博晖创新生物技术集团股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 内 部 控 制 审 计 报 告 大华内字[2025]0011000019 号 北京博晖创新生物技术集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了北京博晖创新生物技术集团股份有限公司（以下 简称博晖创新）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、 《企业内部控制评价指引》的规定，建立健全和有效实施内部控制， 并评价其有效性是企业董事会的责任。 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 ...

审计报告 北京博晖创新生物技术集团股份有限公司 大华审字[2025]0011001222 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 北京博晖创新生物技术集团股份有限公司 审计报告及财务报表 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-109 | 大华会计师事务所（特殊普通合伙） 北京市海 ...

北京博晖创新生物技术集团股份有限公司 独立董事 2024 年度述职报告 （尹俊） 本人尹俊，作为北京博晖创新生物技术集团股份有限公司（以下简称"公 司"或"博晖创新"）第八届董事会独立董事，严格按照《公司法》《证券法》 《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《公司章程》等相关法律法规和规章制度的规定和要求，在 2024 年的工 作中，忠实、勤勉、尽责地履行职务，积极亲自出席相关会议，充分发挥独 立董事的独立性和专业性作用，切实维护了公司和股东尤其是中小股东的利 益。现将 2024 年我履行独立董事职责的情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 尹俊：男，1967 年生，中国国籍，无境外永久居留权，博士研究生学历。曾 任内蒙古乌海市海渤湾区下海勃湾街道办事处行政秘书，内蒙古乌海市海渤湾区 农林局工作人员，内蒙古农牧学院生物工程系讲师，内蒙古农业大学生物工程系 讲师，内蒙古农业大学生物工程学院讲师、副教授、教授。现任本公司独立董事， 内蒙古农业大学生命科学学院教授、博士生导 ...

北京博晖创新生物技术集团股份有限公司 独立董事 2024 年度述职报告 （张晓甦） 本人张晓甦，作为北京博晖创新生物技术集团股份有限公司（以下简称 "公司"或"博晖创新"）第八届董事会独立董事，严格按照《公司法》《证券 法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》及《公司章程》等相关法律法规和规章制度的规定和要求，在 2024 年 的工作中，忠实、勤勉、尽责地履行职务，积极亲自出席相关会议，充分发 挥独立董事的独立性和专业性作用，切实维护了公司和股东尤其是中小股东 的利益。现将 2024 年我履行独立董事职责的情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 （二）独立性情况说明 张晓甦：女，1960 年生，中国国籍，无境外永久居留权，博士学位，副教授。 曾任北京腾信软创科技股份有限公司独立董事。现任本公司独立董事、北京理工 大学副教授。 本人已根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关规定，对报告期内本人是 ...